Actavis plc it has launched a generic version of Intuniv (guanfacine hydrochloride) as part of a settlement agreement with Shire plc. Actavis has begun shipping the product and, under applicable Hatch Waxman rules, is entitled to 180 days of marketing exclusivity, according to Actavis.

Intuniv is a prescription medicine used to treat attention deficit hyperactivity disorder in patients ages 6 to 17. For the 12-month period ending June 30, 2014, Intuniv had US sales of approximately $668 million, according to data from IMS Health and as reported by Actavis.

Source: Actavis